Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

Encision announces financial results for Q1 fiscal year 2016

Encision Inc., a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2016 first quarter that ended June 30, 2015.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

In developed countries like the U.S., Europe and parts of Asia, healthcare leaders are trying to optimize efficiency, systems integration, data analytics and achieve greater productivity. In emerging economies, enabling access to affordable, basic primary care is often the most pressing concern. Healthcare systems around the world face a wide range of difficult challenges. All could benefit from training and education solutions focused specifically on their particular needs.

29 Jul 2015

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.

29 Jul 2015

Point-of-care diagnostics for Ebola

In a recent DECODED research profile, Integrated DNA Technologies (IDT), details how IDT scientists Kristin Beltz and Dr Scott Rose are collaborating with Dr Brian Taylor’s research team at Battelle (Aberdeen, MD, USA) to design and validate a RT-qPCR assay that can detect the Ebola virus in the field.

From Integrated DNA Technologies 28 Jul 2015

Egalet declares pricing of underwritten public offering of common stock

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $11.25 per share.

28 Jul 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

Study: New material that mimics coral could help remove toxic heavy metals from the ocean

A new material that mimics coral could help remove toxic heavy metals like mercury from the ocean, according to a new study published in the Journal of Colloid and Interface Science. The researchers, from Anhui Jianzhu University in China, say their new material could provide inspiration for other approaches to removing pollutants.

25 Jul 2015

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

AcelRx Pharmaceuticals, Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency, has adopted a positive opinion for Zalviso (sufentanil sublingual tablets).

25 Jul 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

For years, a crisis has been brewing in molecular biology. The problem is that antibodies--research tools used to identify key proteins at work in a cell--aren't always what they seem. Unreliable antibodies have led to numerous instances of false findings, failed experiments, and wasted money and samples.

24 Jul 2015

Lupin enters into definitive agreement to acquire GAVIS

Pharma Major Lupin Limited has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., subject to certain closing conditions, in a transaction valued at USD 880 million, cash free and debt free.

23 Jul 2015

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

Enigma Diagnostics Ltd. and Beijing Leadman Biochemistry Co., Ltd. signed a joint venture agreement with the principal goal of delivering the Enigma MiniLab molecular diagnostic Point-of-Care platform into the Chinese health care market to support its growing diagnostic needs.

23 Jul 2015

Common environmental chemicals may act separately or together to increase risk of cancer

Common environmental chemicals assumed to be safe at low doses may act separately or together to disrupt human tissues in ways that eventually lead to cancer, according to a task force of nearly 200 scientists from 28 countries, including one from Oregon State University.

22 Jul 2015

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial.

21 Jul 2015

Managing Director of Messe Düsseldorf issues statement on upcoming MEDICA 2015

To get to the top is difficult; to stay at the top is even more difficult. Every athlete knows that and this also applies to the trade show business.

21 Jul 2015

Valeant Pharmaceuticals enters into definitive agreement to acquire Amoun Pharmaceutical

Valeant Pharmaceuticals International, Inc. today announced that it has entered into a definitive agreement under which Valeant will acquire Mercury (Cayman) Holdings, the holding company of Amoun Pharmaceutical, for consideration of approximately US$800 million, plus contingent payments.

17 Jul 2015

Next-generation tissue implant allows neuroscientists to wirelessly control neurons inside the brains of mice

A study showed that scientists can wirelessly determine the path a mouse walks with a press of a button. Researchers at the Washington University School of Medicine, St. Louis, and University of Illinois, Urbana-Champaign, created a remote controlled, next-generation tissue implant that allows neuroscientists to inject drugs and shine lights on neurons deep inside the brains of mice.

17 Jul 2015

Manufacturing News and Research

Further Reading

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Encision announces financial results for Q1 fiscal year 2016

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

Point-of-care diagnostics for Ebola

Egalet declares pricing of underwritten public offering of common stock

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Study: New material that mimics coral could help remove toxic heavy metals from the ocean

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

3SBio purchases entire equity interest in Zhejiang Wansheng

New Histone Antibody Specificity Database allows scientists to find right antibodies for biomedical research

Lupin enters into definitive agreement to acquire GAVIS

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

Common environmental chemicals may act separately or together to increase risk of cancer

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

Managing Director of Messe Düsseldorf issues statement on upcoming MEDICA 2015

Valeant Pharmaceuticals enters into definitive agreement to acquire Amoun Pharmaceutical

Next-generation tissue implant allows neuroscientists to wirelessly control neurons inside the brains of mice

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®